Discussed issues related to User Fee reauthorization, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
2026 · 1st Quarter (Jan 1 - Mar 31)
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Filed by PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 22, 2026
- Income
- Not reported
- Expenses
- $50,000.00
- Filing UUID
- 86494454-df5b-414d-a84d-6eb68ca17c02
- Termination date
- Not reported
Expense method: C
Literal source text
Lobbying issues and bill citations
Discussed issues related to User Fee reauthorization, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed response to Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
Discussed issues related to User Fee reauthorization, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.